Literature DB >> 20671392

Motor cortex stimulation for intractable neuropathic facial pain related to multiple sclerosis.

Takafumi Tanei1, Yasukazu Kajita, Toshihiko Wakabayashi.   

Abstract

A 33-year-old man presented with ongoing severe right facial pain and sensory disturbances caused by multiple sclerosis (MS). Neuroimaging demonstrated demyelinating lesions in the right dorsal pons and medulla oblongata. The pain was refractory to carbamazepine at 800 mg/day, gabapentin at 1800 mg/day, morphine at 30 mg/day, amitriptyline at 60 mg/day, and diazepam at 4 mg/day, along with twice-monthly ketamine (60 mg) drip infusions. The patient underwent motor cortex stimulation (MCS), resulting in >60% pain relief, reduction in the required doses of pain medications, and discontinuation of ketamine administration. MCS is effective for MS-related neuropathic facial pain.

Entities:  

Mesh:

Year:  2010        PMID: 20671392     DOI: 10.2176/nmc.50.604

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  5 in total

1.  Facial pain as an initial manifestation of intramedullary cervical spinal cord tumor: A case report and literature review.

Authors:  Vidzhai Dzhafarov; Jamil Rzaev; Galina Moysak; Eugenia Voronina
Journal:  Surg Neurol Int       Date:  2020-07-04

2.  Neuromodulation Management of Chronic Neuropathic Pain in The Central Nervous system.

Authors:  Kai Yu; Xiaodan Niu; Bin He
Journal:  Adv Funct Mater       Date:  2020-06-10       Impact factor: 18.808

3.  Motor cortex stimulation for facial chronic neuropathic pain: A review of the literature.

Authors:  Guillermo A Monsalve
Journal:  Surg Neurol Int       Date:  2012-10-31

4.  Neuromodulation for cephalgias.

Authors:  Serge Y Rasskazoff; Konstantin V Slavin
Journal:  Surg Neurol Int       Date:  2013-04-17

Review 5.  Pain in multiple sclerosis: a systematic review of neuroimaging studies.

Authors:  D Seixas; P Foley; J Palace; D Lima; I Ramos; I Tracey
Journal:  Neuroimage Clin       Date:  2014-07-05       Impact factor: 4.881

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.